Last reviewed · How we verify
Trivalent influenza vaccine-licensed
At a glance
| Generic name | Trivalent influenza vaccine-licensed |
|---|---|
| Sponsor | Seqirus |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine (PHASE4)
- Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination (PHASE4)
- Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults (PHASE2)
- Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent influenza vaccine-licensed CI brief — competitive landscape report
- Trivalent influenza vaccine-licensed updates RSS · CI watch RSS
- Seqirus portfolio CI